<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865082</url>
  </required_header>
  <id_info>
    <org_study_id>2125-MST-206</org_study_id>
    <nct_id>NCT03865082</nct_id>
  </id_info>
  <brief_title>Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)</brief_title>
  <official_title>Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idera Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Idera Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy&#xD;
      drugs ipilimumab and nivolumab in different solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label,multi-center, multicohort study of intratumoral tilsotolimod in&#xD;
      combination with nivolumab and ipilimumab for the treatment of specific solid tumors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate the efficacy of intratumoral tilsotolimod in combination with ipilimumab and nivolumab for each cohort</measure>
    <time_frame>ORR defined as a CR or partial response (PR) according to RECIST v1.1, confirmed by imaging ≥ 4 weeks after the initial documentation of response (to occur up to 24 months).</time_frame>
    <description>Efficacy measure by objective response rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response</measure>
    <time_frame>DOR will be evaluated every 8 weeks starting Cycle3 Day1 (each cycle is 28 days) for year 1 then every 12 weeks after the first year through study completion until all study participants have either progressive disease or start new anticancer treatment.</time_frame>
    <description>Durability or response per RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the combination of tilsotolimod with nivolumab and ipilimumab</measure>
    <time_frame>At every study visit (up to 48 months)</time_frame>
    <description>Number of subjects with adverse events as a measure of safety and tolerability including changes in vital signs, electrocardiograms(ECGs), safety and laboratory parameters as assessed by CTCAE v4.03 or higher.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>IO Naive Subjects MSS CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8mg Tilsotolimod by intratumoral injection plus 3mg/kg Nivolumab (every three weeks for four doses followed by 480mg dose every four weeks) and 1mg/kg Ipilimumab every three weeks for four doses intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tilsotolimod</intervention_name>
    <description>9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.</description>
    <arm_group_label>IO Naive Subjects MSS CRC</arm_group_label>
    <other_name>IMO-2125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days.</description>
    <arm_group_label>IO Naive Subjects MSS CRC</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days.</description>
    <arm_group_label>IO Naive Subjects MSS CRC</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be willing and able to sign the informed consent and comply with study&#xD;
             protocol.&#xD;
&#xD;
          2. Must be ≥ 18 years of age (males and females).&#xD;
&#xD;
          3. ≥ 1 lesion accessible for i.t. injection and biopsy(ies).&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 minimum life&#xD;
             expectancy ≥ 4 months.&#xD;
&#xD;
          5. Adequate baseline organ function as defined by:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1500/mm3)&#xD;
&#xD;
               2. Platelet count ≥ 100 x 109/L (100,000/mm3)&#xD;
&#xD;
               3. Hemoglobin ≥ 9.0 g/dL (5.59 mmol/L)&#xD;
&#xD;
               4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine&#xD;
                  clearance of ≥ 40 mL/minute (measured or calculated using the Cockroft-Gault&#xD;
                  formula)&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) ≤ 3 x ULN, alanine aminotransferase (ALT) ≤ 3 x&#xD;
                  ULN; AST/ALT &lt; 5 ULN if liver involvement&#xD;
&#xD;
               6. ≤ 1.5 x ULN, except in subjects with Gilbert's syndrome who must have a total&#xD;
                  bilirubin ≤ 3 mg/dL&#xD;
&#xD;
          6. Women of child bearing potential (WOCBP) and men with WOCBP partners must agree to use&#xD;
             effective contraception methods as defined in the clinical study protocol.&#xD;
&#xD;
          7. For any subjects who received prior approved/investigational i.t. anti-cancer&#xD;
             treatments, the study's Medical Monitor must be consulted before enrollment.&#xD;
&#xD;
        Inclusion Criteria ( MSS CRC IO Naïve)&#xD;
&#xD;
          1. Histologically confirmed advanced, metastatic, or progressive MSS CRC based on either&#xD;
             an analysis of tissue from a prior biopsy or based on tissue from a new biopsy.&#xD;
             Subject's microsatellite/MMR status should be known.&#xD;
&#xD;
          2. Received two prior lines of therapy for advanced or metastatic CRC including&#xD;
             fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Subjects who relapse&#xD;
             within 6 months of adjuvant chemotherapy composed of oxaliplatin and a&#xD;
             fluoropyrimidine will have their adjuvant therapy count as one prior regimen.&#xD;
&#xD;
          3. Documentation of radiologic progression by Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1 during or after previous chemotherapy. Subjects documented&#xD;
             clinical progression may be eligible and must be discussed with the medical monitor to&#xD;
             determine eligibility.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Subject must have completed or completely discontinued any previous cancer-related&#xD;
             treatments before enrollment with necessary windows and wash out periods as defined in&#xD;
             the clinical study protocol.&#xD;
&#xD;
          2. History of interstitial lung disease, pneumonitis, known or suspected autoimmune&#xD;
             diseases (unless for specific diseases as defined in protocol) or human&#xD;
             immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          3. Prior therapy with TLR9 agonist, excluding topical agents.&#xD;
&#xD;
          4. Known hypersensitivity to any study drug component.&#xD;
&#xD;
          5. Treatment with botanical preparations (e.g. herbal supplements or traditional Chinese&#xD;
             medicines) intended for general health support or to treat the disease under study&#xD;
             within 2 weeks prior to treatment.&#xD;
&#xD;
          6. Known or suspected autoimmune diseases. Subjects with type I diabetes mellitus,&#xD;
             hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo,&#xD;
             psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected&#xD;
             to recur in the absence of an external trigger are permitted to be enrolled.&#xD;
&#xD;
             Subject with a requirement of systemic steroids &gt; 10 mg/day of prednisone (or&#xD;
             equivalent) for the 2 weeks preceding start of study treatment.&#xD;
&#xD;
          7. Subject with another primary malignancy that has not been in remission for at least 3&#xD;
             years except for non-melanoma skin cancer, curatively treated localized prostate&#xD;
             cancer with non-detectable prostate specific antigen, cervical carcinoma in situ on&#xD;
             biopsy, or thyroid cancer (except anaplastic).&#xD;
&#xD;
          8. Active systemic infections requiring antibiotics.&#xD;
&#xD;
          9. Active Hepatitis A, B or C infections.&#xD;
&#xD;
         10. Known diagnosis of human immunodeficiency virus (HIV) infection or known acquired&#xD;
             immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be performed at sites&#xD;
             where mandated locally.&#xD;
&#xD;
         11. Women who are breast feeding or pregnant.&#xD;
&#xD;
         12. Prior anaphylactic or other severe infusion reaction associated with human antibody&#xD;
             administration that cannot be managed by standard supportive measurements.&#xD;
&#xD;
         13. Presence of known central nervous system (CNS), meningeal, or epidural metastatic&#xD;
             disease.However, subjects with known brain metastases are allowed if brain metastases&#xD;
             are stable for≥ 4 weeks before the first dose of study treatment. Stable is defined as&#xD;
             neurological symptoms not present or resolved at baseline, no radiological evidence of&#xD;
             progression, and steroid requirement of prednisone ≤ 10 mg/day or equivalent.&#xD;
&#xD;
         14. Subject with unstable and impaired cardiac function or clinically significant cardiac&#xD;
             disease per Investigator's clinical judgment.&#xD;
&#xD;
         15. Has received live attenuated vaccine 30 days before first study dose. Any live&#xD;
             attenuated vaccine [e.g., varicella, zoster, yellow fever, rotavirus, oral polio and&#xD;
             measles, mumps, rubella (MMR)] during treatment and until 100 days post last dose will&#xD;
             be prohibited.&#xD;
&#xD;
        Exclusion Criteria (MSS CRC IO Naïve):&#xD;
&#xD;
          1. Prior therapy with an anti-programmed cell death-1 (PD-1), anti-programmed cell death&#xD;
             ligand-1 (PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory&#xD;
             or co-inhibitory T-cell receptor in an approved or experimental setting.&#xD;
&#xD;
          2. Subjects with BRAF V600E mutations.&#xD;
&#xD;
          3. Subjects with a history of immune-mediated colitis.&#xD;
&#xD;
          4. Subjects who received three or more lines of therapy for advanced or metastatic CRC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner University Medical Center Tucson Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hani Babiker, MD</last_name>
      <phone>520-694-8888</phone>
      <email>hanibabiker@email.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California/ Hoag Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz-Josef Lenz, MD</last_name>
      <phone>323-865-3000</phone>
      <email>lenz@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Overman, MD</last_name>
      <phone>713-792-2828</phone>
      <email>moverman@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Michael Overman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

